HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 5, May 2016 – Healthcare Systems & Policies in Asia       » Understanding Healthcare Policies in the Philippines: Cancer Care       » Young Innovators under 35       » Healthcare Cost Effectiveness in Singapore       » ASLAN Pharmaceuticals Opens China Office       » A Journey Inside the Human Body       » Treatment Brings New Hope for Patients Suffering From Fatal Lung Disease      
INSIDE INDUSTRY
Octa Phillip Bioscience Managers announces first close on new healthcare fund
Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), announced a successful first close on its second fund, the Asia Pacific Healthcare Fund II, which has so far attracted $55 million from Australian Institutions, IOOF and MIESF.

“The growing healthcare and life sciences sector in Australia and across the Asia Pacific region provides a unique investing opportunity, which is much more resilient than traditional commodity markets.” Bioscience Managers’ Managing Director Jeremy Curnock Cook said. “We believe that our fund offers institutional and sophisticated investors a pathway to investing in the sector that is carefully designed to minimize risk and maximize security.”

The fund has already started building its portfolio, investing $3m into ASX listed regenerative medicine company, Avita and is currently assessing a number of other companies.

Bioscience Managers has a global, multi-disciplinary team and a focus on healthcare and life sciences firms that are in or near clinical development. Their “designed for security” risk managed investment approach has resonated with their committed institutions, who recognize that the macroeconomic trends powering global demand for healthcare are set to continue, creating a period of unprecedented opportunities for skilled, specialized fund managers and their investors.

Chief Investment Officer Matt McNamara said, “We are extremely pleased to have completed a first close at $55m in a very difficult market. We would hope to raise $100m or more by our final close.”

With over 170 investments, 40+ IPO's / Reversals across Australia, the USA and Europe and investments in companies such as Chiron, Amgen and Angiotech behind him, Bioscience Managers’ Managing Director Jeremy Curnock Cook, is an expert in the field. Bioscience Managers’ first fund, the IB Australian Bioscience Fund I, is still active, has returned called capital to its investors (as of 30 June 2012) and recorded an annual IRR of 28%[2] (as at 30 Sept 2012) since its inception in 2008. Fund I's investments have included successful Australian companies such as Heartware, Acrux, Pharmaxis, Alchemia and Peplin (acquired by Leo Pharma).

Yet despite the firm's undeniable success, the current financial climate has proved a challenge. “It's inarguable that the current volatility in the financial markets is pulling funds away from growth investments, such as healthcare technology investments, and into more risk averse assets such as cash and bonds. We believe that our investment approach manages risk effectively in an industry seen by some to be a high risk environment. With a proven track record in exceeding investor expectations, we anticipate continuing to attract capital to this and other investment vehicles.” said Curnock Cook.

Fund II will remain open for investment for 12 months from its first close.

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices and Digital Health Technology
July:
Water Technology
August:
Guest Editorial - Antibody Informatics In Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» Editorial Enquiries: biotech_edit@wspc.com
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   Ms PoPo Kwok or Ms Sok Ching Lim/td>
Copyright© 2015 World Scientific Publishing Co Pte Ltd  •  Privacy Policy